Does etanercept increase risk of IBD?
Of the TNF-alpha inhibitors, this alone is linked with inflammatory bowel disease: Danish study
Patients being treated with etanercept appear to be at increased risk of developing inflammatory bowel disease, according to a large Danish study.
Researchers analysed data on more than 17,000 patients who were treated with anti-TNF alpha drugs for indications including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, but excluding inflammatory bowel disease, between 2004 and 2017.
Most received etanercept (9072 people), adalimumab (8355) or infliximab (7344).
They compared these with more than 63,000 patients with rheumatological autoimmune diseases who had not been exposed to the drugs.
